- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2017
- Public Summary Document (PSD) November 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2017 PBAC Meeting - Word
Baricitinib – November 2017
Baricitinib: Tablet 2 mg, Tablet 4 mg; Olumiant®
Last updated
16 March 2018